Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

In this subset of the MAVIDOS trial population, no differences in gestational age or whole‐body minus head DXA outcomes were observed in the babies by maternal randomization group to placebo or 1000 IU cholecalciferol (Table 1C).

Source: Characteristics of participants. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In this study, we used an existing randomized trial to test the hypothesis that maternal gestational vitamin D supplementation would lead to reduced perinatal RXRA locus DNA methylation.

Source: Abstract.

We analyzed RXRA DNA methylation data from the MAVIDOS study, a multicenter, double‐blind, randomized, placebo‐controlled trial of vitamin D supplementation in pregnancy, in which the primary outcome was neonatal bone mass.

Source: Methods.

Participants were randomized to receive either cholecalciferol 1000 IU/day or matched placebo [Merck KGaA, Darmstadt, Germany)/Sharp Clinical Services (previously DHP‐Bilcare), Crickhowell, UK], from before 17 weeks’ gestation until delivery.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Gestational Vitamin D Supplementation Leads to Reduced Perinatal RXRA DNA Methylation: Results From the MAVIDOS Trial

Randomised controlled trial · Journal of Bone and Mineral Research · 2019

Original publication title

Gestational Vitamin D Supplementation Leads to Reduced Perinatal RXRA DNA Methylation: Results From the MAVIDOS Trial

Elizabeth M Curtis; Nevena Krstic; Eloïse Cook; Stefania D'Angelo; Sarah R Crozier; Rebecca J Moon; Robert Murray; Emma Garratt; Paula Costello; Jane Cleal; Brogan Ashley; Nicholas J Bishop; Stephen Kennedy; Aris T Papageorghiou; Inez Schoenmakers; Robert Fraser; Saurabh V Gandhi; Ann Prentice; M Kassim Javaid; Hazel M Inskip; Keith M Godfrey; Christopher G Bell; Karen A Lillycrop; Cyrus Cooper; Nicholas C Harvey; the MAVIDOS Trial Group

© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

ABSTRACT

We have previously demonstrated inverse associations between maternal 25(OH)‐vitamin D status and perinatal DNA methylation at the retinoid‐X‐receptor‐alpha (RXRA) locus and between RXRA methylation and offspring bone mass. In this study, we used an existing randomized trial to test the hypothesis that maternal gestational vitamin D supplementation would lead to reduced perinatal RXRA locus DNA methylation. The Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a multicenter, double‐blind, randomized, placebo‐controlled trial of 1000 IU/day cholecalciferol or matched placebo from 14 weeks’ gestation until delivery.

Umbilical cord (fetal) tissue was collected at birth and frozen at −80°C (n = 453). Pyrosequencing was used to undertake DNA methylation analysis at 10 CpG sites within the RXRA locus (identified previously). T tests were used to assess differences between treatment groups in methylation at the three most representative CpG sites. Overall, methylation levels were significantly lower in the umbilical cord from offspring of cholecalciferol‐supplemented mothers, reaching statistical significance at four CpG sites, represented by CpG5: mean difference in % methylation between the supplemented and placebo groups was −1.98% (95% CI, −3.65 to −0.32, p = 0.02).

ENCODE (Encyclopedia of DNA Elements) evidence supports the functionality of this locus with strong DNase hypersensitivity and enhancer chromatin within biologically relevant cell types including osteoblasts. Enrichment of the enhancer‐related H3K4me1 histone mark is also seen in this region, as are binding sites for a range of transcription factors with roles in cell proliferation, response to stress, and growth factors. Our findings are consistent with previous observational results and provide new evidence that maternal gestational supplementation with cholecalciferol leads to altered perinatal epigenetic marking, informing mechanistic understanding of early life mechanisms related to maternal vitamin D status, epigenetic marks, and bone development. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Authors’ abstract

ABSTRACT

We have previously demonstrated inverse associations between maternal 25(OH)‐vitamin D status and perinatal DNA methylation at the retinoid‐X‐receptor‐alpha (RXRA) locus and between RXRA methylation and offspring bone mass. In this study, we used an existing randomized trial to test the hypothesis that maternal gestational vitamin D supplementation would lead to reduced perinatal RXRA locus DNA methylation. The Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a multicenter, double‐blind, randomized, placebo‐controlled trial of 1000 IU/day cholecalciferol or matched placebo from 14 weeks’ gestation until delivery.

Umbilical cord (fetal) tissue was collected at birth and frozen at −80°C (n = 453). Pyrosequencing was used to undertake DNA methylation analysis at 10 CpG sites within the RXRA locus (identified previously). T tests were used to assess differences between treatment groups in methylation at the three most representative CpG sites. Overall, methylation levels were significantly lower in the umbilical cord from offspring of cholecalciferol‐supplemented mothers, reaching statistical significance at four CpG sites, represented by CpG5: mean difference in % methylation between the supplemented and placebo groups was −1.98% (95% CI, −3.65 to −0.32, p = 0.02).

ENCODE (Encyclopedia of DNA Elements) evidence supports the functionality of this locus with strong DNase hypersensitivity and enhancer chromatin within biologically relevant cell types including osteoblasts. Enrichment of the enhancer‐related H3K4me1 histone mark is also seen in this region, as are binding sites for a range of transcription factors with roles in cell proliferation, response to stress, and growth factors. Our findings are consistent with previous observational results and provide new evidence that maternal gestational supplementation with cholecalciferol leads to altered perinatal epigenetic marking, informing mechanistic understanding of early life mechanisms related to maternal vitamin D status, epigenetic marks, and bone development. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Publication and source details

Original title: Gestational Vitamin D Supplementation Leads to Reduced Perinatal RXRA DNA Methylation: Results From the MAVIDOS Trial

Elizabeth M Curtis; Nevena Krstic; Eloïse Cook; Stefania D'Angelo; Sarah R Crozier; Rebecca J Moon; Robert Murray; Emma Garratt; Paula Costello; Jane Cleal; Brogan Ashley; Nicholas J Bishop; Stephen Kennedy; Aris T Papageorghiou; Inez Schoenmakers; Robert Fraser; Saurabh V Gandhi; Ann Prentice; M Kassim Javaid; Hazel M Inskip; Keith M Godfrey; Christopher G Bell; Karen A Lillycrop; Cyrus Cooper; Nicholas C Harvey; the MAVIDOS Trial Group

Journal of Bone and Mineral Research · 2019

* Address correspondence to: Professor Cyrus Cooper, MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK. E‐mail: cc@mrc.soton.ac.uk
†

EMC, NK, and EC are joint first authors.

‡

KAL, CC, and NCH are joint senior authors.

© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Arthritis Research UKWellcome TrustEuropean Union's Seventh Framework ProgrammeERA‐Net on Biomarkers for Nutrition and HealthMerck GmbH for the kind provision of the Vigantoletten supplement

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T14:11:25.522525+00:00

DOI: 10.1002/jbmr.3603 · PMC6372078